Back to Search
CHARLES RUDIN, M.D., PH.D.
M.D., PH.D.
Hematology & Oncology Physician
NPI: 1467483404IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
D61040(MD)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
UNIVERSITY OF CHICAGO, PRITZKER SCHOOL OF MEDICINE
Class of 1993
Research & Publications (20)
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
PMID 19047285·J Clin Oncol·2009
3-trial
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro.
PMID 19351829·Cancer Res·2009
7-preclinical
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
PMID 19182243·Oncologist·2009
3-trial
Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology.
PMID 19644022·J Mol Diagn·2009
8-other
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.
PMID 18978206·Blood·2009
8-other
Evaluation of 13q14 status in patients with chronic lymphocytic leukemia using single nucleotide polymorphism-based techniques.
PMID 19460942·J Mol Diagn·2009
8-other
To say or not to say: a qualitative study on the disclosure of their condition by human immunodeficiency virus-positive adolescents.
PMID 19306794·J Adolesc Health·2009
8-other
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
PMID 18309947·J Clin Oncol·2008
4-observational
Supplementum 168: Toxoplasmosis during pregnancy and infancy.
PMID 19475733·Swiss Med Wkly·2008
7-preclinical
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
PMID 18381439·Cancer Res·2008
7-preclinical
Round-table multidisciplinary counselling of couples with HIV prior to assisted reproduction.
PMID 18681989·Reprod Biomed Online·2008
3-trial
Management of small-cell lung cancer: incremental changes but hope for the future.
PMID 19133604·Oncology (Williston Park)·2008
6-review
Novel systemic therapies for small cell lung cancer.
PMID 18377849·J Natl Compr Canc Netw·2008
8-other
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
PMID 18281659·J Clin Oncol·2008
3-trial
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
PMID 18166842·J Thorac Oncol·2008
3-trial
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
PMID 18382386·Pediatr Infect Dis J·2008
8-other
Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis.
PMID 18074149·Eur J Pediatr·2008
4-observational
Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
PMID 17971529·J Natl Cancer Inst·2007
7-preclinical
An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b.
PMID 17693652·Ann Oncol·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10065 - Phone
- (646) 888-4336
Quick Facts
- NPI
- 1467483404
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile